Lea Glass‐Marmor

1.5k total citations
27 papers, 820 citations indexed

About

Lea Glass‐Marmor is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Lea Glass‐Marmor has authored 27 papers receiving a total of 820 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pathology and Forensic Medicine, 6 papers in Molecular Biology and 5 papers in Cancer Research. Recurrent topics in Lea Glass‐Marmor's work include Multiple Sclerosis Research Studies (10 papers), Medication Adherence and Compliance (4 papers) and Circadian rhythm and melatonin (3 papers). Lea Glass‐Marmor is often cited by papers focused on Multiple Sclerosis Research Studies (10 papers), Medication Adherence and Compliance (4 papers) and Circadian rhythm and melatonin (3 papers). Lea Glass‐Marmor collaborates with scholars based in Israel, Germany and Spain. Lea Glass‐Marmor's co-authors include Ariel Miller, Rivka Beitner, Tamar Paperna, Idit Lavi, Izabella Lejbkowicz, Daniel Golan, Kläus Müllen, Sara Dishon, Hossam Haick and Elsebeth Staun-Ram and has published in prestigious journals such as PLoS ONE, British Journal of Cancer and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Lea Glass‐Marmor

27 papers receiving 805 citations

Peers

Countries citing papers authored by Lea Glass‐Marmor

Since Specialization

Citations

This map shows the geographic impact of Lea Glass‐Marmor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lea Glass‐Marmor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lea Glass‐Marmor more than expected).

Fields of papers citing papers by Lea Glass‐Marmor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lea Glass‐Marmor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lea Glass‐Marmor. The network helps show where Lea Glass‐Marmor may publish in the future.

Co-authorship network of co-authors of Lea Glass‐Marmor

This figure shows the co-authorship network connecting the top 25 collaborators of Lea Glass‐Marmor. A scholar is included among the top collaborators of Lea Glass‐Marmor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lea Glass‐Marmor. Lea Glass‐Marmor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Personalized Intervention to Improve Medication Adherence for Persons with Multiple Sclerosis 2024 ·Patient Preference and Adherence ·Efrat Neter, (unknown), Lea Glass‐Marmor, (unknown), Idit Lavi, Ariel Miller	3
2	Medication habits among persons with multiple sclerosis 2022 ·Multiple Sclerosis and Related Disorders ·Efrat Neter, Lea Glass‐Marmor, (unknown), Ariel Miller	2
3	Concordance Between Persons with Multiple Sclerosis and Treating Physician on Medication Effects and Health Status 2021 ·Patient Preference and Adherence ·Efrat Neter, Lea Glass‐Marmor, (unknown), Ariel Miller	5
4	Mobile-phone-based e-diary derived patient reported outcomes: Association with clinical disease activity, psychological status and quality of life of patients with multiple sclerosis 2021 ·PLoS ONE ·Daniel Golan, (unknown), Lea Glass‐Marmor, Ariel Miller	4
5	Mobile phone-based e-diary for assessment and enhancement of medications adherence among patients with multiple sclerosis 2020 ·Multiple Sclerosis Journal - Experimental Translational and Clinical ·Daniel Golan, (unknown), Lea Glass‐Marmor, Ariel Miller	11
6	Multiple modality approach to assess adherence to medications across time in Multiple Sclerosis 2020 ·Multiple Sclerosis and Related Disorders ·Efrat Neter, (unknown), Lea Glass‐Marmor, Idit Lavi, (unknown), (unknown), Ariel Miller	8
7	Exhaled Breath Markers for Nonimaging and Noninvasive Measures for Detection of Multiple Sclerosis 2017 ·ACS Chemical Neuroscience ·Yoav Y. Broza, Lior Har‐Shai, Raneen Jeries, John C. Cancilla, Lea Glass‐Marmor, Izabella Lejbkowicz, José S. Torrecilla, Xuelin Yao, Xinliang Feng, Akimitsu Narita, Kläus Müllen, Ariel Miller, Hossam Haick	42
8	Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis 2015 ·Journal of the Neurological Sciences ·Ziv Savin, Izabella Lejbkowicz, Lea Glass‐Marmor, Idit Lavi, Sara Rosenblum, Ariel Miller	17
9	The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis 2013 ·Brain Behavior and Immunity ·Daniel Golan, Elsebeth Staun-Ram, Lea Glass‐Marmor, Idit Lavi, Orit Rozenberg, Sara Dishon, Mira Barak, Sophia Ish‐Shalom, Ariel Miller	55
10	Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis 2010 ·Journal of Cellular and Molecular Medicine ·(unknown), Tamar Paperna, (unknown), (unknown), Lea Glass‐Marmor, Ariel Miller	52
11	Immunomodulation by chronobiologically-based glucocorticoids treatment for multiple sclerosis relapses 2009 ·Journal of Neuroimmunology ·Lea Glass‐Marmor, Tamar Paperna, (unknown), Ariel Miller	18
12	Translation towards personalized medicine in Multiple Sclerosis 2008 ·Journal of the Neurological Sciences ·Ariel Miller, Nili Avidan, (unknown), Lea Glass‐Marmor, Izabella Lejbkowicz, Ron Y. Pinter, Tamar Paperna	22
13	Serum anti-Glc(α1,4)Glc(α) antibodies as a biomarker for relapsing–remitting multiple sclerosis 2006 ·Journal of the Neurological Sciences ·Mikael Schwarz, Larissa Spector, (unknown), (unknown), Lea Glass‐Marmor, Arnon Karni, Nir Dotan, Ariel Miller	49
14	Matrix Metalloproteinase-9, Its Tissue Inhibitor(TIMP)-1 and CRP in Alzheimer’s Disease 2005 ·European Neurology ·(unknown), (unknown), Lea Glass‐Marmor, Ariel Miller	11
15	Bio-markers of disease activity and response to therapy in multiple sclerosis 2004 ·Clinical Neurology and Neurosurgery ·Ariel Miller, Lea Glass‐Marmor, Michal Abraham, Iris Grossman, Sarah Shapiro, (unknown)	31
16	Ca2+-induced changes in energy metabolism and viability of melanoma cells 1999 ·British Journal of Cancer ·Lea Glass‐Marmor, (unknown), Rivka Beitner	17
17	Detachment of glycolytic enzymes from cytoskeleton of melanoma cells induced by calmodulin antagonists 1997 ·European Journal of Pharmacology ·Lea Glass‐Marmor, Rivka Beitner	52
18	Effects of carbamylcholine and pyridostigmine on cytoskeleton-bound and cytosolic phosphofructokinase and ATP levels in different rat tissues 1996 ·General Pharmacology The Vascular System ·Lea Glass‐Marmor, (unknown), Rivka Beitner	7
19	Effects of Carbamylcholine and Pyridostigmine on Mitochondrial-Bound Hexokinase in Skeletal Muscle and Heart 1996 ·Biochemical and Molecular Medicine ·Lea Glass‐Marmor, Rivka Beitner	7
20	Calmodulin antagonists decrease glucose 1,6-bisphosphate, fructose 1,6-bisphosphate, ATP and viability of melanoma cells 1996 ·European Journal of Pharmacology ·Lea Glass‐Marmor, (unknown), Rivka Beitner	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact